New data from the PARTNER 2A trial and the SAPIEN 3 trial and the benefits to intermediate risk patients will be discussed in detail during this webcast. This subset of intermediate risk patients receiving transcatheter aortic valve replacement (TAVR) have less risk of stroke and mortality than those receiving surgery. Patient selection, the importance of heart teams, and center experience improve patient outcomes. These two trials will establish the benefits of TAVR to the intermediate risk population and how the future of TAVR will change with more trials and use in low risk patients. read more...
Click Here to access this CME Program
April 8th, 2016
October 8th, 2016